98%
921
2 minutes
20
The amide bond is one of the most pivotal functional groups in chemistry and biology. It is also the key component of proteins and widely present in synthetic materials. The majority of studies have focused on the formation of the amide group, but its postmodification has scarcely been investigated. Herein, we successfully develop the Michael additions of amide to acrylate, acrylamide, or propiolate in the presence of phosphazene base at room temperature. This amide Michael addition is much more efficient when the secondary amide instead of the primary amide is used under the same conditions. This reaction was applied to postfunctionalize poly(methyl acrylate--acrylamide), P(MA--Am), and it is shown that the amide groups of P(MA--Am) could be completely modified by ,-dimethylacrylamide (DMA). Interestingly, the resulting copolymer exhibited tailorable fluorescence with emission wavelength ranging from 380 to 613 nm, which is a desired property for luminescent materials. Moreover, the emissions of the copolymer increased with increasing concentration in solution for all excitation wavelengths from 320 to 580 nm. Therefore, this work not only develops an efficient -BuP-catalyzed amide Michael addition but also offers a facile method for tunable multicolor photoluminescent polymers, which is expected to find a wide range of applications in many fields, such as in anticounterfeiting technology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.0c15260 | DOI Listing |
Arch Orthop Trauma Surg
September 2025
Department of Clinical Research, Research Group Michael T. Hirschmann, Regenerative Medicine & Biomechanics, University of Basel, Basel, Switzerland.
Introduction: The aim of this systematic review was to evaluate the efficiency of different analgetic regimes used in clinical practice in reducing postoperative pain and cumulative opioid consumption following total knee arthroplasty (TKA).
Materials And Methods: A systematic search was conducted on PubMed, Embase and Scopus according to PRISMA guidelines in order to identify appropriate studies published between 2010 and 2025, which investigated different oral or intravenous analgesic strategies (duloxetine, acetaminophen, corticosteroids, opioids, nonsteroidal anti-inflammatory drugs (NSAIDs) and gabapentinoids) in populations of patients receiving TKA by having as primary outcome the quantification of postoperative pain scores or opioid consumption.
Results: Out of the 1069 identified articles, 63 met the inclusion criteria.
Sci Rep
August 2025
Institute for Hygiene and Public Health, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Cefiderocol-resistant bacteria pose a growing concern in both clinical and environmental settings. This study investigates cefiderocol-resistant bacteria in wastewater from six German tertiary care hospitals. A total of 36 samples were analysed using a culture-dependent approach involving cefiderocol pre-enrichment, yielding 97 cefiderocol-resistant isolates-primarily Enterobacter roggenkampii, Klebsiella oxytoca, Serratia marcescens, and Citrobacter farmeri.
View Article and Find Full Text PDFACS Catal
February 2025
Division of Chemical Biology & Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States; Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
Blasticidin S is a peptidyl nucleoside that blocks protein synthesis in prokaryotes and eukaryotes. It is widely used in molecular biology as a selection agent. Despite its utility, the biosynthetic origin of its 2',3'-unsaturated-4'-aminoacyl-4'-deoxyhexopyranose core is only partially understood.
View Article and Find Full Text PDFCancer
August 2025
Department of Oncology, Instituto Oncologico Fundacion Arturo Lopez Perez, Hospital Clinico Universidad de Chile, Santiago, Chile.
Background: Patients with recurrent glioblastoma (GBM) have a poor prognosis and limited treatment options. The authors report the efficacy and safety of lenvatinib plus pembrolizumab in participants with recurrent GBM enrolled in the phase 2, multicohort LEAP-005 study (NCT03797326).
Methods: Eligible participants had histologically confirmed GBM (World Health Organization grade IV) with disease progression since previous treatment, and one or more prior lines of therapy.
Antimicrob Agents Chemother
September 2025
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Although the article by J Càmara, I Grau, A González-Díaz, N Santos, et al. (Antimicrob Agents Chemother 69:e00237-25, 2025, https://doi.org/10.
View Article and Find Full Text PDF